Phase 2
N=243
Selegiline Patch for Treatment of Nicotine Dependence
Tobacco Use Disorder
Bottom Line
View on ClinicalTrials.gov: NCT01330030 ↗Enrolled (actual)
243
Serious AEs
0.0%
Results posted
Apr 2016
Primary outcome: Primary: Expired-air Carbon Monoxide Confirmed Smoking Abstinence — 24; 25 participants not smoking
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Selegiline (Drug); matching placebo (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Stanford University
- Primary completion
- Aug 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Expired-air Carbon Monoxide Confirmed Smoking Abstinence |
24; 25 | — |
Summary
Relapse to smoking is a common problem affecting smokers who seek treatment. The purpose of this study is examine whether selegiline, given in the form of a skin patch, is effective in stopping smoking.
Eligibility Criteria
Inclusion Criteria
- Smokes greater than 20 cigarettes per day
Exclusion Criteria
- History of Parkinson's disease, high blood pressure, or severe liver or kidney disease
- Current substance abuse
- Mental illness
- Skin conditions that could interfere with patch use
- Using antidepressant medications (e.g., levodopa/carbidopa, methyldopa, or any MAO inhibitor)
- Pregnant or breastfeeding
Data sourced from ClinicalTrials.gov (NCT01330030). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.